Roche’s SARS-CoV-2 Antigen Test Receives CE mark For Self Testing of COVID-19 at Home

 Roche’s SARS-CoV-2 Antigen Test Receives CE mark For Self Testing of COVID-19 at Home

Roche Reports New Interim Data of JEWELFISH & RAINBOWFISH Studies for Evrysdi (risdiplam) to Treat Spinal Muscular Atrophy

Shots:

  • Roche received a CE mark for its SARS-CoV-2 Ag self-test nasal at home setting for COVID 19. The test will be available in countries accepting the CE mark
  • The early version of the test is available in the EU under special approval pathways since Feb, 2021. The test can be performed by individuals using nasal swap & can deliver results in 15mins
  • The test demonstrates 91.1% relative sensitivity and 99.6 % overall relative specificity from the combined study. Additionally, Roche offers NAVIFY Pass digital solution that enables individuals to share their test results and vaccine status through a unique QR code

Click here to­ read full press release/ article | Ref: Roche | Image: Roche

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post